Linked Life Data

12621383

Source:http://linkedlifedata.com/resource/pubmed/id/12621383

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2003-3-6
pubmed:abstractText
Atomoxetine is a treatment for attention-deficit/hyperactivity disorder and is primarily eliminated via cytochrome P4502D6 (CYP2D6). The pharmacokinetics of atomoxetine and its primary metabolites were investigated in 10 adults with hepatic impairment (6 moderate, 4 severe) and 10 age- and sex-matched control subjects, all being genotyped as CYP2D6 extensive metabolizers.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0009-9236
pubmed:author
pubmed:issnType
Print
pubmed:volume
73
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
178-91
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2003
pubmed:articleTitle
Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
pubmed:affiliation
Department of Clinical Pharmacology, Lilly Research Laboratories, Lilly Development Centre SA, Parc Scientifique de Louvain-La-Neuve, Rue Granbonpré 11, 1348 Mont-Saint-Guibert, France. chalon_stephane_a@lilly.com
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't